{"id":"tar-200","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":{"chemblId":"CHEMBL2108232","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, TAR-200 prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.","oneSentence":"TAR-200 is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:33.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT04919512","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-07","conditions":"Urinary Bladder Neoplasms","enrollment":163},{"nctId":"NCT04658862","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-07","conditions":"Urinary Bladder Neoplasms","enrollment":518},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT04640623","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-18","conditions":"Urinary Bladder Neoplasms","enrollment":220},{"nctId":"NCT07309445","phase":"","title":"A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-04-01","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":150},{"nctId":"NCT06877676","phase":"","title":"Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use","status":"APPROVED_FOR_MARKETING","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":""},{"nctId":"NCT03404791","phase":"PHASE1","title":"A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Urinary Bladder Neoplasms","enrollment":35},{"nctId":"NCT03518320","phase":"PHASE1","title":"Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer","status":"TERMINATED","sponsor":"Taris Biomedical LLC","startDate":"2019-01-02","conditions":"Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B","enrollment":13},{"nctId":"NCT02722538","phase":"PHASE1","title":"Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Taris Biomedical LLC","startDate":"2016-05-31","conditions":"Urinary Bladder Cancer","enrollment":23},{"nctId":"NCT02720367","phase":"PHASE1","title":"Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Taris Biomedical LLC","startDate":"2016-01","conditions":"Urinary Bladder Cancer","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-17000139","Gemcitabine-Releasing Intravesical System","Gemcitabine-Releasing Intravesical System (GemRIS)"],"phase":"phase_3","status":"active","brandName":"TAR-200","genericName":"TAR-200","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAR-200 is a monoclonal antibody targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}